Fresh Tracks Therapeutics, Inc, A Clinical-Stage Pharmaceutical Company Aiming To Disrupt Existing Treatment Paradigms By Developing Innovative, Differentiated Prescription Therapeutics For The Treatment Of Autoimmune, Inflammatory, And Other Debilitating Diseases, Has Announced Publication Of Data From Preclinical Studies Of Frtx-02, A Potential First-In-Class, Orally Bioavailable Dyrk1A Inhibitor, In The Journal Of Translational Autoimmunity. The Paper Shows Frtx-02 To Be A Potent And Selective Inhibitor Of Dyrk1A With The Potential To Restore Immune Homeostasis By Regulating Adaptive And Innate Immune System Responses In Models Of Various Autoimmune And Inflammatory Diseases.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!